Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual B Lymphoblastic Leukemia
Authors: Seheult Jansen N , Weybright Matthew J , Shi Min , Jevremovic Dragan , Chiu April , Timm Michael M , Otteson Gregory E , Olteanu Horatiu , Horna Pedro 
Published: December 2024

Background: Flow cytometry (FC) is widely utilized for the identification of minimal residual disease (MRD) in B acute lymphoblastic leukemia (BALL), providing an essential laboratory indicator for prognostic assessment and therapeutic management. Unfortunately, the high level of expertise required, long manual analysis time, and complexity of FC data files limit the offering of this testing to selected reference laboratories.

Methods: We developed an artificial intelligence (AI) pipeline to automatically enhance unaltered FC files, minimizing the expertise and manual analysis time needed to detect BALL-MRD on a single-tube 10-color panel (CD10, CD19, CD20, CD22, CD24, CD34, CD38, CD45, CD58, CD66c). Raw FC files corresponding to peripheral blood or bone marrow specimens from 171 BALL MRD positive cases (MRD &lt; 5%, median = 0.11%, 107 patients), and 89 MRD-negative cases (63 patients) were processed through our CCADDAS (Clustering and Classification of All events, Dimensionality reduction, Downsampling and Aberrancy Scaling) pipeline on a cloud environment (Google Vertex AI). Automated processing steps included elimination of acquisition errors (FlowCut), state-of-the-art clustering (PARC), dimensionality reduction (UMAP), cluster-based anomaly detection compared to negative controls (24 bone marrow aspirates and 7 peripheral bloods), and cluster-informed downsampling with preservation of low-event subsets. In addition, a deep neural network (DNN) trained on expert-defined subpopulations from negative controls was included for automatic gating of normal subsets (Tensorflow v2). AI-enhanced data files were analyzed using a general purpose flow cytometry analysis software (Kaluza v 3.5, Beckman Coulter), and %MRD estimates compared to reported results based on expert analysis of original FC files.

Results: Cluster-informed downsampling reduced the number of cells per case to be manually analyzed from 1.2 million to 155,884 cells on average (87% cellularity reduction); resulting in a smaller FC data file (from 64.5 MB to 13.7 MB; 79% data reduction). Importantly, low-level MRD events were adequately preserved after downsampling (median 100% retention for both MRD&lt;0.01% and MRD 0.01-1%). True number of events were accurately estimated on gated subsets using an “upsampling factor” parameter [observed # events x mean (upsampling factor)]. Gating of normal subsets was completely automated using a DNN classifier parameter. Identification of MRD was aided by an AI-generated “aberrancy scale” parameter that discriminated BALL (median: 991) from both benign mononuclear cells (median: 486, p &lt; 0.0001) and background B-lymphoid cells (median: 379, p &lt; 0.0001), with a performance (AUC: 0.98 and 0.94 for mononuclear and B-lymphoid cells, respectively) superior to CD20 (0.54 and 0.69), CD38 (0.60 and 0.81), CD45 (0.75 and 0.74), CD58 (0.52 and 0.89), CD66c (0.56 and 0.72) and all other antigens studied. The use of AI-enhanced files reduced manual analysis time from 14.16 minutes (SD = 3.7) to 1.05 minutes (SD = 0.6) per case, on average (p &lt; 0.0001) (93% reduction). BALL MRD was detected in all positive cases above clinically relevant threshold (≥0.01%, as recommended by NCCN guidelines), and in 28 of 32 (88%) cases below this threshold, with excellent quantitative correlation with conventional analysis on original FC files (linear regression slope = 1.18, intercept = 0.04%, R squared = 0.92, P &lt; 0.0001).

Conclusion: We introduce a largely unsupervised AI pipeline that transforms raw BALL-MRD FC data into a markedly smaller, AI-annotated and software-agnostic FC file, including comparison to normal controls. This CCADDAS pipeline simplifies and accelerates detection of BALL-MRD in clinical diagnostics, reducing number of cells analyzed by 87% and manual analysis time by 93%, without impacting test performance. Moreover, CCADDAS can be utilized for any labroatory-developed BALL-MRD assay, and its small-sized export is compatible with any clinical FC software, computing platform and analysis strategy. Adoption of CCADDAS is likely to facilitate the implementation of BALL-MRD FC analysis by more clinical laboratories.